Frontlight ResearchEarly access
Enrolling by invitationNo phase
Safety and Effectiveness Study of SQ-Kyrin TMVr System for Degenerated Mitral Regurgitation
Key facts
- Who runs it
- Shanghai Shenqi Medical Technology Co., Ltd
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 118 people, planned
- Started
- 15 Oct 2021
- Expected to end
- 15 Dec 2028
- Type of study
- Interventional
- Treatments tested
- transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)
- Record updated
- 20 June 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 38 criteriaShow less
Who can take part
- Severe MR ≥3+ as determined by transthoracic echocardiography (TTE)
- STS risk score results show that patients at high risk for traditional surgery or patients who cannot tolerate traditional thoracotomy: Subjects judged to be refractory to mitral valve surgery due to a ≥ 8% risk of death from STS surgery for surgical mitral valve replacement, or a ≥ 6% risk of death from STS surgery for surgical mitral valve repair, or because of any of the following risk factors:; Porcelain aorta or active ascending aortic plaque; Mediastinum treated with radiotherapy; Past mediastinitis; Left ventricular ejection fraction (LVEF) <40%; Presence of a patent coronary bypass implant; Acceptance of two or more cardiothoracic surgeries; Liver cirrhosis; Other surgical risk factors
- Patients with Degenerated MR (Degenerated MR)
- Age ≥ 18 years old, regardless of gender
- Classification of cardiac function: NYHA class II, III or ambulatory class IV
- Patients assessed by a multidisciplinary cardiac team as very high-risk or unsuitable for routine mitral valve surgery
- Be able to understand the objective of the trial, and volunteered to participate and signed the Informed Consent Form, willing to accept the relevant examination and clinical follow-up
- Left ventricular end-systolic diameter (LVESD)≤60mm
- The MR beam mainly originates from the A2/P2 area
- Mitral valve disease prolapse lesion area width≤15mm, prolapse height≤10mm, effective length of anterior and posterior valve leaflets>10mm
- Mitral valve effective orifice area (EOA) ≥ 4.0cm2
- No obvious calcification of mitral valve leaflets
- Patient anatomy allows atrial septum approach
Who cannot take part
- Patients who are extremely frail and cannot tolerate general anesthesia surgery or is in the state of shock requiring circulatory support
- History of mitral valve surgery
- Patients with infective endocarditis or suggestive of active infection
- Complicated with severe untreated coronary artery disease
- Patients with pulmonary hypertension (pulmonary systolic blood pressure>70mmHg)
- Mitral regurgitation due to active rheumatic heart disease or rheumatic etiology
- Patients with definite coagulation disorders and severe coagulation system diseases
- Patients with stroke or transient cerebral ischemic attack within 30 days
- Patients with other valve disease requiring surgery or interventional therapy
- Patients with severe macrovascular disease requiring surgical treatment
- Patients with inappropriate anatomical structures of the heart and valves indicated by imaging examinations
- Known allergy to contrast agents and nickel-titanium memory alloy products
- Patients with diseases that seriously affect the evaluation of treatment, such as patients with severe neurological lesions affecting cognitive ability, patients with malignant tumors, etc
- Left ventricular ejection fraction <20%
- Severe renal insufficiency (eGFR ≤ 25 mL/min) or requiring chronic renal replacement therapy
- Patients with transthoracic echocardiographic evidence suggesting moderate-severe to severe right ventricular dysfunction
- Patients diagnosed with hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis
- Patients with clear contraindications to the use of anticoagulants
- Any intracardiac mass, left ventricular or atrial thrombus detected on transthoracic echocardiography
- Severe tricuspid TR
- Severe symptomatic carotid stenosis (>70% on ultrasonography) or carotid stenting within 30 days
- R<testing systolic blood pressure 90 mmHg or >160 mmHg
- Patient life expectancy < 12 months
- Patients with severe thoracic deformity
- Women who are pregnant, breastfeeding, or planning to become pregnant within the next 12 months
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To verify the safety and effectiveness of transcatheter mitral valve clip delivery system and steerable guide catheter produced by Shanghai Shenqi Medical Technology Co., Ltd.in patients with moderate-severe or severe degenerated mitral regurgitation (DMR).
The group in the trial
- transcatheter mitral valve clip delivery system and steerable guide catheter (Shenqi Medical)Treatment being tested
The principle of this product is the transcatheter interventional edge-to-edge repair technology (edge-to-edge repair). The core technology is to treat the regurgitation by edge-to-edge suturing the mitral valve. The double holes are set in the mitral valve (A2/P2 zone) or the edges in A1/P1 or A3/P3 zones are apposed and closed to treat regurgitation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multicenter, Single-Arm Clinical Trial to Assess the Safety and Efficacy of a Transcatheter Mitral Valve Clip Delivery System With Steerable Guide Catheter in Patients With Moderate-Severe or Severe Degenerative Mitral Regurgitation (DMR)
- Publications
- Multicenter Evaluation of an Edge-to-Edge Repair System in High-Risk Patients With Degenerative Mitral Regurgitation.Structural heart : the journal of the Heart Team, 2026
- Record updated
- 20 June 2024